1-3 of 3
Herbert Opitz
Close
Sort by
Journal Articles

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia

Clinical Trials & Observations
Maria Domenica Cappellini, Alan Cohen, Antonio Piga, Mohamed Bejaoui, Silverio Perrotta, Leyla Agaoglu, Yesim Aydinok, Antonis Kattamis, Yurdanur Kilinc, John Porter, Marcello Capra, Renzo Galanello, Slaheddine Fattoum, Guillermo Drelichman, Carmelo Magnano, Monica Verissimo, Miranda Athanassiou-Metaxa, Patricia Giardina, Alexandra Kourakli-Symeonidis, Gritta Janka-Schaub, Thomas Coates, Christiane Vermylen, Nancy Olivieri, Isabelle Thuret, Herbert Opitz, Catherine Ressayre-Djaffer, Peter Marks, Daniele Alberti
Journal: Blood
Blood (2006) 107 (9): 3455–3462.
https://doi.org/10.1182/blood-2005-08-3430
Published: 2006
Journal Articles

Semi-Quantitative Assessment of Hemosiderin Distribution Accurately Reflects Reductions in Liver Iron Concentration Following Therapy with Deferasirox (Exjade ® , ICL670) or Deferoxamine in Patients with Transfusion-Dependent Anemia.

Yves Deugnier, Bruno Turlin, Martine Ropert, Mohamed Bejaoui, Miranda Athanassiou-Metaxa, Holger Cario, Elliott Vichinsky, Herbert Opitz, Catherine Ressayre-Djaffer, Bertrand Rabault, John Ford
Journal: Blood
Blood (2005) 106 (11): 2708.
https://doi.org/10.1182/blood.V106.11.2708.2708
Published: 2005
Journal Articles

Phase III Evaluation of Once-Daily, Oral Therapy with ICL670 (Exjade®) Versus Deferoxamine in Patients with β-Thalassemia and Transfusional Hemosiderosis.

Maria Cappellini, MD, Mohamed Bejaoui, MD, Silverio Perrotta, MD, Leyla Agaoglu, MD, Antonios Kattamis, MD, Patricia Giardina, MD, Gritta Janka-Schaub, MD, Herbert Opitz, PhD, Catherine Ressayre-Djaffer, PhD, Daniele Alberti, MD
Journal: Blood
Blood (2004) 104 (11): 3619.
https://doi.org/10.1182/blood.V104.11.3619.3619
Published: 2004